Merit

For research use only. Not for human consumption. Not medical advice — consult a licensed clinician.

GLP-1 / Metabolic

Tirzepatide

Also known as: Tirzepatide (GIP/GLP-1 dual receptor agonist — Mounjaro, Zepbound)

Tirzepatide is a unimolecular dual GIP and GLP-1 receptor agonist with a half-life of approximately 5 days, enabling once-weekly subcutaneous dosing. It is FDA-approved as Mounjaro for type 2 diabetes (2022), Zepbound for chronic weight management in adults with obesity or overweight with a weight-related comorbidity (2023), and Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity (2024). It carries a BOXED WARNING for thyroid C-cell tumors and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Real-time market data

Pricing for Tirzepatide

Live vendor pricing, normalized to $/mg so sizes compare fairly — fused with each seller's Merit trust score and latest independent COA purity. Prices refresh daily.

Average price

$6.92/mg

range $0.00–$93.33/mg

Sellers

74

from $0.00

45-day trend

+28.7%

vs 45-day avg $/mg

68 of 74 sellers have a current price· 46 stale listings hidden (not seen in 7 days)

Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.

Independent evidence

COAs for Tirzepatide

388 third-party tests across 43 vendors. Each card links to the full report.

All 388 COAs for Tirzepatide →
Measured purity 82.3%–100.0% across 257 COAs
Measured purity over time
✓ Vendor-published
99.59 %
Jul 2026
Kovera Labs

For

Tirzeptide

by Ignite Peptides· batch IP-2607-127

COA on file
✓ Vendor-published
99.51 %
Jul 2026
Kovera Labs

For

Tirzepatide

by Ignite Peptides· batch IP-2607-797

COA on file
Aggregated · 3rd-party listing
99.91 %
Jul 2026
ILS Labs Strong

For

Tirzepatide

by NG Peptide· batch TRZ20-14

Aggregated · 3rd-party listing
99.22 %
Jul 2026
ILS Labs Strong

For

Tirzepatide

by Aspire Peptides· batch TR10-032026-1

Aggregated · 3rd-party listing
99.81 %
Jul 2026
ILS Labs Strong

For

Tirzepatide

by Aspire Peptides· batch TR15-032026-1

Aggregated · 3rd-party listing
99.68 %
Jun 2026
ILS Labs Strong

For

Tirzepatide

by Orbitrex Peptides· batch 2G30726

Aggregated · 3rd-party listing
99.95 %
Jun 2026
Freedom Diagnostics Moderate

For

Tirzepatide

by Ion Peptide· batch ION2T20-06242026

Aggregated · 3rd-party listing
99.89 %
Jun 2026
Freedom Diagnostics Moderate

For

Tirzepatide

by Profound Aminos· batch Clear Cap/Bronze Crimp

✓ Vendor-published
99.11 %
Jun 2026
TrustPointe Analytics Moderate

For

Tirzepatide

by Peptide Partners· batch SPL-4130

COA on file
Aggregated · 3rd-party listing
99.88 %
Jun 2026
ILS Labs Strong

For

Tirzepatide

by NG Peptide· batch TRZ30-13

Aggregated · 3rd-party listing
99.82 %
Jun 2026
ILS Labs Strong

For

Tirzepatide

by Peptide Plugs· batch 005-B-SM

Aggregated · 3rd-party listing
99.90 %
Jun 2026
ILS Labs Strong

For

Tirzepatide

by NG Peptide· batch TRZ60-04

Aggregated · 3rd-party listing
99.03 %
Jun 2026
ILS Labs Strong

For

Tirzepatide

by Voltera Sciences· batch TR60.05.28.26

Aggregated · 3rd-party listing
99.77 %
Jun 2026
Janoshik Analytical Limited

For

Tirzepatide

by EZ Peptides· batch EZP-2P2005162026-04

✓ Vendor-published
99.77 %
Jun 2026
Janoshik Analytical Limited

For

Tirzepatide

by EZ Peptides· batch EZP-2P2005162026-04

COA on file
✓ Vendor-published
98.49 %
May 2026
Kovera Labs

For

ION-2T

by Ion Peptide· batch ION2T30-05122026

COA on file
✓ Vendor-published
99.96 %
May 2026
Kovera Labs

For

ION-2T

by Ion Peptide· batch ION2T10-05122026

COA on file
Aggregated · 3rd-party listing
99.77 %
May 2026
Janoshik Analytical Limited

For

Tirzepatide

by EZ Peptides· batch EZP-2P3004212026-03

✓ Vendor-published
99.80 %
May 2026
Janoshik Analytical Limited

For

Tirzepatide

by EZ Peptides· batch EZP-2P3004212026-03

COA on file
✓ Vendor-published
99.96 %
May 2026
Kovera Labs

For

ION-2T

by Ion Peptide· batch ION2T100-05142028

COA on file
✓ Vendor-published
99.78 %
May 2026
Kovera Labs

For

ION-2T

by Ion Peptide· batch ION2T20-05142026

COA on file
✓ Vendor-published
99.96 %
May 2026
Kovera Labs

For

Tirzeppatide

by Reta One Labs· batch TR300626

COA on file
Aggregated · 3rd-party listing
99.29 %
May 2026
Horizon Analytical

For

Tirzepatide

by Pepsgpt· batch P-9887337-P

Aggregated · 3rd-party listing
99.85 %
May 2026
Kovera Labs

For

Tirzepatide

by Glacier Aminos· batch TIR20GA-04

Research depth

23 citations indexed for Tirzepatide

All research on Tirzepatide →

Study · 2026

Effect of short-term tirzepatide treatment on mean platelet volume in patients with obesity: a retrospective controlled study

Objective Obesity is associated with chronic low-grade inflammation, increased cardiovascular risk, and alterations in platelet indices [1-5]. Mean platelet volume (MPV) is an easily obtainable surrogate marker that has been linked to platelet activation and inflammatory burden [4, 6-8].

Study · 2026

Tirzepatide as a therapeutic tool for kidney impairment in obesity: insights from a real-world study

Background Obesity is a major risk factor for chronic kidney disease (CKD), contributing to kidney dysfunction through metabolic alterations and chronic inflammation.

Study · 2026

Tirzepatide, cardiovascular outcomes and mortality in obesity and diabetes: a systematic review and meta-analysis

Aims To assess the effect of tirzepatide, a glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide agonist, on cardiovascular outcomes and mortality in subjects with overweight/obesity, or type 2 diabetes mellitus (T2DM).

Study · 2026

Effects of Tirzepatide in Obesity-Related HFpEF by Sex: A Prespecified Secondary Analysis From the SUMMIT Trial

Background The SUMMIT trial showed that the long-acting glucose-dependent insulinotropic polypeptide receptor and glucagon-like peptide-1 receptor agonist tirzepatide decreased risk of cardiovascular death or worsening heart failure (HF) in patients with obesity-related heart failure with preserved ejection fraction (H…

Study · 2026

Comparative Cardiovascular Outcomes of Tirzepatide and Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease

Background To evaluate the association between tirzepatide use and 1-year risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease, compared with GLP-1 (glucagon-like peptide-1) receptor agonists.

Study · 2026

Safety Profile of Tirzepatide in Real-World Clinical Practice: A Pharmacovigilance Study Using the FAERS Database

Aims Tirzepatide, a first-in-class dual GIP/GLP-1 receptor agonist, was approved by the FDA for type 2 diabetes mellitus (2022) and chronic weight management (2023). Despite superior efficacy in trials, its real-world safety profile remains incompletely characterised.